Defining partial response in inflammatory bowel disease: a Delphi consensus and economic evaluation
The concept of partial responders has been defined in four clinical scenarios. Patients achieving prolonged remission could provide 55%-70% savings in non-pharmacological resource use and associated costs. Our study could help healthcare professionals in decision-making, ultimately improving patient care.
Authors
- José Germán Sánchez‐Hernandez (ORCID: https://orcid.org/0000-0002-2985-3686)
- Jordi Guardiola (ORCID: https://orcid.org/0000-0002-0464-241X)
- Luis A. Menchen (ORCID: https://orcid.org/0000-0001-9490-3726)
- Eugenia Vispo
- Iago Rodríguez–Lago (ORCID: https://orcid.org/0000-0003-1133-4578)
- Vicente Merino‐Bohórquez (ORCID: https://orcid.org/0000-0002-0315-3411)
- Eugeni Domènech
- Beatriz Garcillán
- Elia Moreno-Cubero
Institutions
- Universidad Complutense de Madrid (ES)
- Johnson & Johnson (United States) (US)
- Universidad de Deusto (ES)
- Bellvitge University Hospital (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitario Virgen Macarena (ES)
- Complejo Hospitalario de Salamanca (ES)
- Hospital de Galdakao (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Johnson & Johnson (Brazil) (BR)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1177/17562848251360907
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Eli Lilly and Company
- Pfizer
- Biogen
- Celltrion
- Eusko Jaurlaritza
- Tillotts Pharma